CNP-104 Data Update: 1-Year Results Show Lasting Improvements in PBC Recent phase 2a results show CNP-104 nanoparticle therapy yields durable 1-year improvements in liver stiffness and cholestasis for patients with PBC.

The nanoparticle therapy CNP-104 achieved sustained biochemical and prognostic gains in patients with primary biliary cholangitis (#PBC) unresponsive to standard treatments, according to 1-year data from a phase 2a study (#NCT05104853).

Read more: https://bit.ly/4shv7Id

#RareDisease #CNP104